Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698898 | 0.76 | ALDH1A1 (0.56) | LMNACA12CA1CA2CA3 | |
| SCHEMBL11244303 | 0.74 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL11244305 | 0.74 | ALDH1A1 (0.42) | LMNACA12CA1CA2CA3 | |
| Ethylene Glycol SCHEMBL5092855 | 0.72 | ALDH1A1 (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL15511368 | 0.72 | CA1 (0.41) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2813031 | 0.69 | ALDH1A1 (0.53) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13441949 | 0.69 | LMNA (0.39) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2913712 | 0.68 | ALDH1A1 (0.40) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1225667 | 0.68 | ALDH1A1 (0.43) | LMNAALDH1A1PKM | |
| SCHEMBL8629351 | 0.67 | ALDH1A1 (0.42) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322597-B1 | PROCESS AND INTERMEDIATES | GLAXOSMITHKLINE LLC (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-1322597-A4 | PROCESS AND INTERMEDIATES | SMITHKLINE BEECHAM CORP (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6884874-B2 | Process and intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040014980-A1 | Such as n-methyl-alanine derivatives; for preparing antibody/maytansinoid complexes | SMITHKLINE BEECHAM PLC | 2004-01-22 | — | — | US | disclosed |
| EP-1322597-A1 | PROCESS AND INTERMEDIATES | SmithKline Beecham Corporation (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6570024-B2 | N-methyl-L-alanine derivatives derivatives used for preparing cell binding agent/maytansinoid complexes | SMITHKLINE BEECHAM CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20020156318-A1 | Process and intermediates | GLAXOSMITHKLINE LLC | 2002-10-24 | — | — | US | disclosed |
| WO-2002022554-A1 | PROCESS AND INTERMEDIATES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014980-A1 | Such as n-methyl-alanine derivatives; for preparing antibody/maytansinoid complexes | HGFAC, ANPEP, AAAS | LMNA 2177/4885CA12 1735/4885CA1 762/4885 |
| US-20020156318-A1 | Process and intermediates | HGFAC, MTAP, SPR | LMNA 703/4885CA12 2982/4885CA1 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.